Tianlong Enhances Blood Safety with Advanced Screening Solutions

On November 28, 2025, Tianlong Science and Technology, based in Xi’an, China, reaffirmed its dedication to global transfusion safety by unveiling an innovative nucleic acid blood screening solution on World AIDS Day. This fully integrated system combines high automation with high-sensitivity nucleic acid testing (NAT) reagents, allowing for the earlier detection of low-viral-load infections, a critical step in minimizing the risk of transfusion-transmitted HIV.

Tianlong’s initiative emphasizes the importance of blood safety as an effective defense against transfusion-transmitted infections. By enhancing screening accuracy, the company enables laboratories to identify HBV, HCV, HIV-1, and HIV-2 in the early stages of infection. This commitment not only supports global public health efforts but also reinforces trust in the safety of blood donations.

Automated Workflow for Efficient Blood Screening

Central to Tianlong’s blood screening solution is the Aurora PANA X6 Fully Automated Nucleic Acid Extraction System, designed specifically for blood centers and large-scale screening initiatives. When paired with the Gentier 96 Real-time PCR System, the platform facilitates a streamlined sample-in, result-out process. This includes original tube loading, barcode identification, automated capping and decapping, direct sample pooling, nucleic acid extraction, and PCR setup.

The end-to-end automation significantly reduces manual steps, thereby lowering the risk of contamination and enhancing operational safety. With the capability to process up to 576 samples per run and 1,152 samples per day, the Aurora PANA X6 meets the demands of high-volume blood screening.

Flexible Testing Modes and Enhanced Biosafety

This advanced system allows for direct pooling into deep-well plates, which eliminates the need for additional collection tubes. Laboratories can choose between individual testing and 6-in-1 pooled testing, balancing efficiency with sensitivity. To ensure reliable performance, the platform incorporates independent work zones, HEPA filtration, UV disinfection, controlled airflow, and an anti-drip design, all contributing to robust biosafety in laboratory environments.

The high-sensitivity NAT reagents provided by KHB complement the automated platform, utilizing qualitative real-time PCR in an integrated format that combines extraction and amplification. These reagents are specifically designed to detect HBV, HCV, HIV-1, and HIV-2 even at low viral loads, facilitating the identification of window-period infections. This capability is vital in reducing the risk of transfusion-transmitted diseases and enhancing the overall safety of blood supplies.

On this World AIDS Day, the emphasis on early-window detection not only showcases Tianlong’s commitment to technology but also highlights its role in protecting lives connected to blood donation and transfusion.

A Commitment to Safer Transfusions

Li Ming, CEO of Tianlong, stated, “On World AIDS Day, we are reminded that every safe transfusion represents a promise of protection for another human life. Our mission is to equip laboratories with solutions that enhance accuracy, strengthen biosafety, and support the global effort to prevent HIV transmission.”

Founded in 1997, Tianlong Science and Technology is a pioneer in genetic testing and molecular diagnostics. Together with its group company, Shanghai Kehua Bio-engineering Co., Ltd. (KHB), the organization has established five core technology platforms: immunodiagnostics, biochemistry, molecular diagnostics, point-of-care testing (POCT), and mass spectrometry. These platforms specialize in the research, development, and manufacturing of instruments and in vitro diagnostic (IVD) reagents, offering comprehensive solutions across various sectors, including clinical diagnostics, blood centers, disease control, veterinary epidemic prevention, and food safety.

For further information, visit Tianlong’s official website or their social media channels on LinkedIn, Facebook, and Twitter.